SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0269881107079865v1
22/2/210    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Dell'Osso, B.
Right arrow Articles by Altamura, A C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dell'Osso, B.
Right arrow Articles by Altamura, A C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series

Bernardo Dell'Osso

Department of Psychiatry, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico, Milan, Italy, bernardo.dellosso{at}policlinico.mi.it

Emanuela Mundo

Department of Psychiatry, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico, Milan, Italy

Donatella Marazziti

Department of Psychiatry, Neurobiology, Pharmacology and Biotechnology, University of Pisa, Italy

A Carlo Altamura

Department of Psychiatry, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico, Milan, Italy

Obsessive compulsive disorder (OCD) is a chronic disorder, currently recognized as one of the most common psychiatric disorder as well as one of the most disabling of all medical disorders. OCD is characterized by high rates of partial and/or absent response to standard, recommended treatments (serotonin reuptake inhibitors and psychotherapy). Recent investigation showed that Venlafaxine, a dual serotonin and norepinephrine reuptake inhibitor (SNRI), may be a valid alternative for some treatment-refractory patients. We present the cases of four OCD patients with comorbid mood or anxiety disorders, who were treated with serotonin reuptake inhibitors (SRIs) at adequate doses for at least 12 weeks, showing partial/no response. Patients were then switched to Duloxetine up to 120 mg/day and followed up for 12 weeks. Three out of four patients showed a Yale-Brown Obsessive Compulsive Scale

(Y-BOCS) score reduction ≥35%. Duloxetine may be helpful in patients with treatment-resistant OCD, although larger and controlled studies are warranted to confirm this preliminary observation.

Key Words: obsessive compulsive disorder (OCD) • treatment-resistance • serotonin and norepinephrine reuptake inhibitors (SNRIs) • Duloxetine

This version was published on March 1, 2008

Journal of Psychopharmacology, Vol. 22, No. 2, 210-213 (2008)
DOI: 10.1177/0269881107079865
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement